CYP-006
Diabetic Foot Ulcers
PreclinicalActive
Key Facts
About Cynata Therapeutics
Cynata develops off-the-shelf stem cell therapies using its scalable Cymerus platform to treat inflammatory and ischemic conditions.
View full company profileTherapeutic Areas
Other Diabetic Foot Ulcers Drugs
| Drug | Company | Phase |
|---|---|---|
| PEP Biologic™ | Intent Biologics | Unknown |
| TOP-N53 | Topadur Pharma | Phase 2 |
| IonoJet™ | Origin | Phase 3 |
| FGF-1 | Zhittya Genesis Medicine | Phase 2 |
| CXCL12 Formulation for DFU | ViCapsys | Pre-clinical |
| NovoSorb BTM | PolyNovo | Clinical Investigation |
| EPIFIX® / AMNIOFIX® | MiMedx Group | Post-Market Study |
| Dermagraft | Organogenesis | Approved/Commercial |